Seminars in Radiation Oncology
Volume 13, Issue 3 , Pages 346-356, July 2003

Radiation-associated cardiovascular disease: manifestations and management

  • M.Jacob Adams

      Affiliations

    • Department of Pediatrics, University of Rochester School of Medicine and Dentistry and Golisano Children’s Hospital at Strong, Rochester, NY USA
    • Department of Community and Preventive Medicine, and Radiation Oncology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
  • ,
  • Steven E Lipshultz

      Affiliations

    • Department of Pediatrics, University of Rochester School of Medicine and Dentistry and Golisano Children’s Hospital at Strong, Rochester, NY USA
    • Department of Community and Preventive Medicine, and Radiation Oncology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
  • ,
  • Cindy Schwartz

      Affiliations

    • Department of Pediatrics, Division of Pediatric Oncology, Johns Hopkins School of Medicine, Baltimore, MD, USA
  • ,
  • Luis F Fajardo

      Affiliations

    • Department of Pathology, Stanford University School of Medicine, Palo Alto, CA, USA
  • ,
  • Veronique Coen

      Affiliations

    • Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
  • ,
  • Louis S Constine

      Affiliations

    • Department of Pediatrics, University of Rochester School of Medicine and Dentistry and Golisano Children’s Hospital at Strong, Rochester, NY USA
    • Corresponding Author InformationAddress reprint requests to Louis S. Constine, MD, Department of Radiation Oncology, University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, Box 647, Rochester, NY 14642, USA

Abstract 

Irradiation of the heart incidental to the treatment of malignancies can cause a spectrum of cardiovascular complications. These include pericarditis, myocardial fibrosis, muscular dysfunction, valvular abnormalities, and conduction disturbances. Survivors of Hodgkin’s disease and breast cancer survivors treated with radiotherapy after mastectomy appear to be the groups at highest risk for radiation-associated cardiovascular disease. Although modern techniques of chest radiotherapy have decreased its frequency by reducing the dose and volume of radiation exposure to the heart, survivors treated with radiation remain at increased risk of cardiovascular disease. The risk of fatal cardiovascular disease increases with younger age at treatment, longer follow-up, and higher dose volumes of exposure to the heart. Certain chemotherapeutic agents, such as anthracyclines, also increase the risk of damage to the heart. Cardiac damage associated with radiotherapy may be progressive. Screening of survivors may help identify those at highest risk for serious cardiovascular disease. The broad range of radiation-associated cardiovascular disease makes it necessary for survivors to be examined with multiple screening modalities, although data do not exist to support definitive recommendations on test frequency.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported by the National Institute of Cancer (CA-79060); National Heart, Lung, and Blood Institute (HL-53392), (5K30HL04161), Preventive Cardiology Training Grant (1T32HL07937) and Wilmot Cancer Research Fellowship of the James P. Wilmot Foundation.

PII: S1053-4296(03)00026-2

doi:10.1016/S1053-4296(03)00026-2

Seminars in Radiation Oncology
Volume 13, Issue 3 , Pages 346-356, July 2003